Veradermics, Incorporated (MANE) Stock

NYSE: MANEHealthcare company in the biotechnology industry, based in New Haven, CT.

Veradermics stock price chart

MANE stock quote & key statistics

Veradermics earnings per share

Income →
Earnings per share

Veradermics revenue & net income

Income →
RevenueNet income

Veradermics annual financials

Income statement →
Veradermics, Incorporated revenue, net income and EPS by fiscal year
Fiscal yearRevenueNet incomeEPS
FY2025$0-$70.0M-$104.54
FY2024$0-$26.5M—
FY2023$0-$16.5M—

Fiscal year ending December 31. Source: company filings via EODHD.

About Veradermics, Incorporated

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum.

Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.

Veradermics stock FAQ

What is the Veradermics stock ticker symbol?

Veradermics, Incorporated trades on the NYSE under the ticker symbol MANE.

What sector and industry is Veradermics in?

Veradermics, Incorporated is classified in the Healthcare sector, Biotechnology industry.

How many employees does Veradermics have?

Veradermics, Incorporated has about 37 full-time employees.

What were Veradermics's revenue and earnings last fiscal year?

Veradermics reported revenue of $0 and net income of -$70.0M in fiscal 2025, with earnings per share of -$104.54.

Is Veradermics in the Russell 2000?

Yes. Veradermics, Incorporated (MANE) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Veradermics go public?

Veradermics stock began trading on February 4, 2026.

Russell 2000 Biotechnology stocks

All Russell 2000 →